Machine learning algorithms able to predict the prognosis of gastric cancer patients treated with immune checkpoint inhibitors

Figure 4 Performance in the four subgroups when XGBoost is used to predict the patient’s overall survival and progression-free survival. A: The performance of XGBoost in predicting overall survival for female patients, male patients, non-surgically treated patients, and surgically treated patients; B: The performance of XGBoost in predicting progression-free survival for female patients, male patients, non-surgically treated patients, and surgically treated patients. NPV: Negative predictive value; PPV: Positive predictive value.